Eligard four-month formulation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Atrix/Sanofi-Synthelabo's prostate cancer therapy Eligard (leuprolide acetate for injectable suspension) is approved Feb. 13 in a 30 mg, four-month formulation. The hormone therapy was previously approved in 7.5 mg (one-month) and 22.5 mg (three-month) formulations. Studies in additional formulations are underwa